Skip to main content

Market Overview

Novartis Stops Iscalimab Trial In Kidney Transplant Patients

Share:
Novartis Stops Iscalimab Trial In Kidney Transplant Patients
  • Novartis AG (NYSE: NVS) has halted a Phase 2 trial of CFZ533 (iscalimab) in kidney transplant patients.
  • The decision follows interim data that showed iscalimab was not as good as tacrolimus-based treatment in preventing organ rejection.
  • Iscalimab's study in liver transplant continues, and additional studies exploring the drug as a potential treatment in other conditions.
  • Novartis is continuing to review the data from the CIRRUS-1 study. Once complete, the company will share the results with the broader scientific community.
  • Price Action: NVS shares closed 0.54% lower at $92.15 on Thursday.
 

Related Articles (NVS)

View Comments and Join the Discussion!

Posted-In: Briefs kidney disease Phase 2 TrialBiotech News Health Care General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com